Zolpidem modified-release in insomnia
Authors Cynthia Kirkwood, Jason Neill, Ericka Breden
Published 15 November 2007 Volume 2007:3(5) Pages 521—526
Cynthia Kirkwood1, Jason Neill2, Ericka Breden3
1Department of Pharmacy; 2School of Pharmacy, Virginia Commonwealth University; 3Virginia Commonwealth University Medical Center, Richmond, VA, USA
Abstract: Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release tablet indicated for the management of induction of sleep and sleep maintenance. The pharmacokinetics of the drug are similar to those of immediate-release zolpidem. Two double-blind, placebo-controlled, parallel-group trials demonstrated efficacy in adults and elderly patients treated with zolpidem MR for 3 weeks without significant impairment in next-day psychomotor functioning. The most common adverse effects with zolpidem MR were dizziness, somnolence, and headache. A starting dose of zolpidem MR 12.5 mg is recommended for adults and 6.25 mg for elderly patients.
Keywords: zolpidem modified-release, hypnotics, insomnia